SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 104 500 KRW -0.19%
Market Cap: 8.2T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SK Biopharmaceuticals Co Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash Interest Paid
â‚©8.1B
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cash Interest Paid
â‚©12.1B
CAGR 3-Years
62%
CAGR 5-Years
30%
CAGR 10-Years
26%
Hanmi Science Co Ltd
KRX:008930
Cash Interest Paid
â‚©10.1B
CAGR 3-Years
115%
CAGR 5-Years
54%
CAGR 10-Years
18%
Hanmi Pharm Co Ltd
KRX:128940
Cash Interest Paid
â‚©26.2B
CAGR 3-Years
9%
CAGR 5-Years
3%
CAGR 10-Years
7%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash Interest Paid
â‚©1.4B
CAGR 3-Years
61%
CAGR 5-Years
43%
CAGR 10-Years
17%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cash Interest Paid
â‚©7.7B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
-2%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
8.2T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.

Intrinsic Value
42 433.46 KRW
Overvaluation 59%
Intrinsic Value
Price

See Also

What is SK Biopharmaceuticals Co Ltd's Cash Interest Paid?
Cash Interest Paid
8.1B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Cash Interest Paid amounts to 8.1B KRW.

What is SK Biopharmaceuticals Co Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
22%

Over the last year, the Cash Interest Paid growth was 133%. The average annual Cash Interest Paid growth rates for SK Biopharmaceuticals Co Ltd have been 22% over the past three years .

Back to Top